| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Eizen Joshua M | Chief Operating Officer and Chief Legal Officer | C/O AN2 THERAPEUTICS, INC., 1300 EL CAMINO REAL, SUITE 100, MENLO PARK | /s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen | 07 Jan 2026 | 0001949621 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ANTX | Common Stock | Sale | $17,948 | -17,923 | -10% | $1.00 | 159,430 | 05 Jan 2026 | Direct | F1, F2, F3 |
| transaction | ANTX | Common Stock | Sale | $7,014 | -6,931 | -4.3% | $1.01 | 152,499 | 06 Jan 2026 | Direct | F1, F3 |
| Id | Content |
|---|---|
| F1 | Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026. |
| F2 | This transaction was executed in multiple trades at prices ranging from $1.001 to $1.003 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| F3 | Includes (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 60,000 RSUs which vest as follows: 25% of the RSUs vest on January 1, 2025, 50% of the RSUs vest on January 1, 2026, and 25% of the RSUs vest on July 1, 2026, (c) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, and (d) 58,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service as of such date. |
Chief Operating Officer and Chief Legal Officer